Don't call GW Pharmaceuticals (NASDAQ: GWPH) a cannabis stock around the company's CEO, Justin Gover. He said at the Morgan Stanley Global Healthcare Conference on Wednesday that it's "frustrating" when GW is listed among cannabis stocks. Gover stated emphatically, "We're a biotech company."
Of course, GW Pharmaceuticals is often labeled a cannabis stock or marijuana stock, and for a good reason: The company focuses on developing cannabis-derived drugs. But Gover's point is that GW's business and regulatory environment is much different than that of most companies whose stocks are grouped in the cannabis stock category.
Gover didn't vent for too long at the Morgan Stanley conference, though. Here are four other things he said that investors interested in GW Pharmaceuticals will want to know.